Colchicine in pericarditis: Why aren't we using it more?

Pericarditis, an inflammatory condition affecting the pericardium, presents with chest pain, pericardial friction rub, and characteristic ECG changes. While non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin form the cornerstone of initial therapy, the addition of colchicine has been shown to improve outcomes, particularly in preventing recurrent episodes.^1,2,4 This benefit extends to both initial acute episodes and recurrent pericarditis, a condition that can severely impact a patient's quality of life.^1,3,4

The mechanism of action for colchicine in pericarditis is rooted in its anti-inflammatory and immunomodulatory properties. It inhibits neutrophil chemotaxis and reduces inflammasome activation, thereby dampening the inflammatory cascade that drives pericardial inflammation. This targeted action helps to resolve the acute episode and, importantly, prevents the chronic inflammatory state that predisposes to recurrence. Understanding this mechanism is key to appreciating why it is not merely an adjunct but a vital component of therapy.

The evidence for colchicine

Clinical experience and guideline recommendations consistently support the use of colchicine in acute pericarditis.⁴ Its inclusion in treatment protocols is based on its ability to reduce the rate of recurrent pericarditis and the incidence of incessant or constrictive pericarditis.^1-4 The drug also helps to shorten the duration of symptoms and improve the response to conventional anti-inflammatory therapy.^1,4 But despite this clear evidence, many clinicians hesitate, often citing concerns about side effects or uncertainty regarding the optimal regimen.

Colchicine has shown particular utility in preventing the cycle of inflammation and recurrence that can trap patients in a chronic disease state.^2,4 For patients who experience recurrent episodes, the impact on daily life can be substantial, leading to frequent hospital visits and prolonged periods of disability.³ This is a vital area where colchicine provides a tangible benefit, breaking the inflammatory feedback loop. For a deeper dive into managing these challenging cases, our previous coverage on steroid-dependent pericarditis offers further insights.

Dosing and duration: getting it right

The primary reason for colchicine's underuse or suboptimal use often stems from confusion surrounding its dosing and duration. The drug has a narrow therapeutic window, and inappropriate dosing can lead to either ineffective treatment or significant gastrointestinal side effects. Standard practice dictates a weight-adjusted regimen to minimise adverse events while maximising efficacy. For patients weighing over 70 kg, the recommended dose is typically 0.5 mg twice daily. For those weighing 70 kg or less, a dose of 0.5 mg once daily is usually sufficient. This weight-based approach is important for patient tolerability and treatment adherence.

The duration of colchicine therapy is equally important. For an initial episode of acute pericarditis, treatment should generally continue for at least three months.¹ In cases of recurrent pericarditis, a longer duration, often six months or more, is recommended.¹ Gradual tapering of the dose, rather than abrupt discontinuation, is also advised to prevent rebound inflammation and recurrence. This prolonged treatment course is often overlooked, leading to premature cessation and subsequent relapse. Clinicians should consult a comprehensive resource like the Oxford Handbook of Cardiology for detailed guidance on these protocols.

Managing adverse effects and drug interactions

The most common adverse effects of colchicine are gastrointestinal, including diarrhoea, nausea, and abdominal cramps.⁴ These are typically dose-dependent and can often be managed by reducing the dose or by taking the medication with food. Less common but more serious side effects include myopathy and bone marrow suppression, particularly in patients with renal or hepatic impairment, or those on concomitant medications that inhibit cytochrome P450 3A4 (CYP3A4) or P-glycoprotein. Careful patient selection and monitoring are therefore essential.

The potential for drug interactions is a significant consideration. Colchicine is metabolised by CYP3A4 and is a substrate for P-glycoprotein. Concomitant use with strong inhibitors of these pathways, such as clarithromycin, diltiazem, verapamil, or cyclosporine, can significantly increase colchicine plasma concentrations, leading to toxicity. Clinicians must meticulously review a patient's medication list before initiating colchicine and consider dose adjustments or alternative therapies if significant interactions are anticipated. This vigilance is paramount to patient safety.

Why it remains underused

Despite the clear benefits and established guidelines, colchicine remains underused.⁴ A significant factor is the historical perception of colchicine as a drug with a narrow therapeutic index and a high incidence of side effects, largely based on older, higher-dose regimens used for conditions like gout. Modern dosing strategies for pericarditis are much lower and better tolerated.⁴ Another barrier is the lack of familiarity among some clinicians with the specific dosing and duration recommendations for pericarditis, leading to a reluctance to prescribe.

The complexity of managing recurrent pericarditis, which often involves a multidisciplinary approach, also contributes to the underutilisation of colchicine.³ Patients may cycle through various specialists, each with differing levels of familiarity with the drug's role in this specific context. This fragmentation of care can lead to missed opportunities for effective prophylaxis. Our previous article, Colchicine in acute pericarditis: why it remains underused, explores these systemic issues in greater detail.

Looking ahead: improving adherence

Improving adherence to colchicine guidelines requires a multi-pronged approach. Education for clinicians on appropriate dosing, duration, and management of side effects is essential. Clear, concise guidelines that are easily accessible at the point of care can also help. Patient education is equally important, ensuring they understand the rationale for prolonged therapy and how to manage potential side effects. Empowering patients to adhere to their treatment regimen is vital for preventing recurrence and improving long-term outcomes.

The development of new anti-inflammatory agents for pericarditis may also influence colchicine's role, but for now, it remains a cornerstone of therapy.² The challenge is not in the drug's efficacy, but in its consistent and correct application.⁴ The field continues to explore novel therapies, such as those targeting interleukin-1 pathways, which offer alternatives for refractory cases.² Our coverage on rilonacept and IL-1 blockade provides context on these emerging treatments.

The long-term implications of untreated or inadequately treated pericarditis, including the risk of constrictive pericarditis, highlight the importance of optimal management. Colchicine, when used correctly, offers a straightforward and effective strategy to mitigate these risks.⁴ The ongoing task for clinicians is to integrate this evidence into routine practice, ensuring that patients receive the full benefit of this established therapy. The next step for the field is to ensure that these guidelines are not just published, but truly implemented.